Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 7/20 | 0.48 |
| ▸ | CTSS | P25774 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242610 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL863895 | 0.89 | CTSK (0.48) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL3773280 | 0.89 | CTSK (0.48) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL863894 | 0.89 | CTSK (0.48) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL17277929 | 0.88 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL2721298 | 0.88 | CYP1A2 (0.68) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL2463121 | 0.88 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL21873981 | 0.88 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL2721300 | 0.88 | CYP1A2 (0.68) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL14914482 | 0.88 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924332-B1 | PRODUCTION PROCESSES OF S- AND O-DIACYLATED GAMMA-GLUTAMYL-CYSTEAMINE PRODRUGS | UNIV OF SUNDERLAND (GB) | 2024-11-06 | — | — | EP | disclosed |
| US-12060315-B2 | Production processes of S- and O-diacylated gamma-glutamyl-cysteamine prodrugs | UNIVERSITY OF SUNDERLAND (GB) | 2024-08-13 | — | — | US | disclosed |
| US-20220106267-A1 | Production Processes of S- and O-Diacylated Gamma-Glutamyl-Cysteamine Prodrugs | UNIVERSITY OF SUNDERLAND (GB) | 2022-04-07 | — | — | US | disclosed |
| EP-3924332-A1 | PRODUCTION PROCESSES OF S- AND O-DIACYLATED GAMMA-GLUTAMYL-CYSTEAMINE PRODRUGS | University of Sunderland (GB) | 2021-12-22 | — | — | EP | disclosed |
| CN-113423688-A | Process for the production of prodrugs of S-and O-diacylated gamma-glutamyl-cysteamine | 桑德兰大学 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020165601-A1 | PRODUCTION PROCESSES OF S- AND O-DIACYLATED GAMMA-GLUTAMYL-CYSTEAMINE PRODRUGS | UNIVERSITY OF SUNDERLAND (GB) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020165601-A1 | PRODUCTION PROCESSES OF S- AND O-DIACYLATED GAMMA-GLUTAMYL-CYSTEAMINE PRODRUGS | UNIVERSITY OF SUNDERLAND (GB) | 2020-08-20 | — | — | WO | disclosed |
| US-8841476-B2 | Preparation of crystalline ezatiostat hydrochloride ansolvate form D | TELIK, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841476-B2 | Preparation of crystalline ezatiostat hydrochloride ansolvate form D | TELIK, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120277439-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND y-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | TANAKA KEIGO (JP) | 2012-11-01 | — | — | US | disclosed |
| US-8188119-B2 | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same | EISAI R&D MANAGEMENT CO., LTD (JP) | 2012-05-29 | — | — | US | disclosed |
| WO-2011156061-A1 | PREPARATION OF CRYSTALLINE EZATIOSTAT HYDROCHLORIDE ANSOLVATE FORM D | TELIK, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| US-20110301376-A1 | PREPARATION OF CRYSTALLINE EZATIOSTAT HYDROCHLORIDE ANSOLVATE FORM D | TELIK, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110301376-A1 | PREPARATION OF CRYSTALLINE EZATIOSTAT HYDROCHLORIDE ANSOLVATE FORM D | TELIK, INC. | 2011-12-08 | — | — | US | disclosed |
| EP-2351752-A1 | PYRIDINE DERIVATIVE HAVING SUBSTITUTED HETERO RING AND SUBSTITUTED y-GLUTAMYLAMINO GROUP, AND ANTI-FUNGAL AGENT COMPRISING SAME | Eisai R&D Management Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20100105737-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND gamma-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105737-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND gamma-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | ASNS, ERG28, GLUL | CYP1A2 231/4885CYP2C9 511/4885CYP2C19 442/4885 |
| US-20120277439-A1 | PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND y-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME | ASNS, GLUL, IL4I1 | CYP1A2 92/4885CYP2C9 359/4885CYP2C19 254/4885 |
| US-20220106267-A1 | Production Processes of S- and O-Diacylated Gamma-Glutamyl-Cysteamine Prodrugs | GGH, QPCT, CTH | CYP1A2 150/4885CYP2C9 49/4885CYP2C19 88/4885 |
| US-12060315-B2 | Production processes of S- and O-diacylated gamma-glutamyl-cysteamine prodrugs | GGH, QPCT, CTH | CYP1A2 150/4885CYP2C9 49/4885CYP2C19 88/4885 |
| US-20110301376-A1 | PREPARATION OF CRYSTALLINE EZATIOSTAT HYDROCHLORIDE ANSOLVATE FORM D | EZR, PCSK9, PEPD | CYP1A2 373/4885CYP2C9 243/4885CYP2C19 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.